My ePortfolio Register   

Five-year follow-up of nivolumab in NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.04.17
Views: 552

Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA

Prof Brahmer speaks with ecancer at AACR 2017 about the long-term survivors of the CA209-003 study, who received nivolumab for advanced non-small cell lung cancer having at least one prior treatment.

She compares the 5 year survival in this group against historic rates, 16% v 4%, and highlights PD-L1 staining as a means to highlight best-responders.

You can read more about these findings here, and watch Prof Brahmer present the data at the conference here.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence